Please login to the form below

Not currently logged in
Email:
Password:

EMA recruits patient voices for its management board

Continues its drive to embed patients' values within drug assessment

EMAThe European Medicine Agency (EMA) has appointed two new patient organisation representatives to its management board.

Ilaria Passarani and Yann Le Cam will be responsible for ensuring the views and needs of patients are taken into account over the next three years.

Passarani currently serves as head of the food and health department at the European Consumer Organisation (BEUC), while Le Cam is chief executive and co-founder of the European Organisation for Rare Diseases (Eurordis).

Also joining the EMA's board is Tonio Borg, who will represent the European Parliament alongside Björn Lemmer who has been reappointed to this role.

Borg is a former European commissioner for health, while Lemmer was a member of the National Commission on Prescription of Drugs in Germany.

Meanwhile, representing healthcare professionals' organisations, Wolf-Dieter Ludwig has been re-appointed to the management board. Ludwig leads the haematology, oncology, tumor immunology and palliative care department at Helios Klinikum Berlin-Buch, a hospital in Germany.

In 2014 the EMA piloted a scheme to involve patients in the assessment of the benefits and risks of medicines in its scientific advisory committee.

The project invited patients to present their views on medicines under deliberation by the agency for which there was an unmet medical need and no clear decision by the regulatory committee.

While patients did not take part in any actual decision-making, the pilot brought a day-to-day understanding of the impact on quality of life that these medicines offered - an alternative viewpoint to those of other stakeholders.

Article by
Rebecca Clifford

17th June 2016

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...